2-amino-6-(4-methoxyphenyl)-4-(1H-pyrrol-2-yl)pyridine-3-carbonitrile

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-amino-6-(4-methoxyphenyl)-4-(1H-pyrrol-2-yl)pyridine-3-carbonitrile
• 化学式: C₁₇H₁₄N₄O
• 分子量: 290.32
• InChiKey: MFFIFWYCQRBZBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  87.7
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
  申请人：Pharmacia Corporation

  公开号：US20040127519A1

  公开（公告）日：2004-07-01

  A method is described for inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, where the method involves administering to the subject an anminocyanopyridine MK-2 inhibiting compound, or a pharmaceutically acceptable salt thereof.

  本文描述了一种抑制需要抑制的受试者中的有丝分裂原活化蛋白激酶激活蛋白激酶-2的方法，其中该方法涉及向受试者给予一种抑制MK-2的氨基氰基吡啶化合物或其药学上可接受的盐。
• Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase-2
  申请人：Pharmacia Corporation

  公开号：US20040142978A1

  公开（公告）日：2004-07-22

  Aminocyanopyridine compounds are described which can inhibit mitogen activated protein kinase-activated protein kinase-2. Pharmaceutical compositions and kits that contain these compounds are also described.

  描述了可抑制丝裂原活化蛋白激酶-活化蛋白激酶-2 的氨基氰吡啶化合物。还描述了含有这些化合物的药物组合物和试剂盒。
• METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS
  申请人：Pharmacia Corporation

  公开号：EP1569645A2

  公开（公告）日：2005-09-07
• AMINOCYANOPYRIDINE INHIBITORS OF MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2
  申请人：Pharmacia Corporation

  公开号：EP1569932A1

  公开（公告）日：2005-09-07
• [EN] METHOD OF USING AMINOCYANOPYRIDINE COMPOUNDS AS MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITORS<br/>[FR] PROCEDE D'UTILISATION DE COMPOSES D'AMINOCYANOPYRIDINE EN TANT QU'INHIBITEURS DE LA PROTEINE MAPKAP KINASE-2
  申请人：PHARMACIA CORP

  公开号：WO2004054505A2

  公开（公告）日：2004-07-01

  A method is described for inhibiting mitogen activated protein kinase-activated protein kinase-2 in a subject in need of such inhibition, where the method involves administering to the subject an anminocyanopyridine MK-2 inhibiting compound, or a pharmaceutically acceptable salt thereof.